Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 435 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... December 16, 2021 Man Offers Free Lawn Mowing Service To Elderly And Veterans August 28, 2021 ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... June 23, 2021 Load more HOT NEWS How to Support a Spouse or Partner During Cancer Treatment by... Perioperative Chemotherapy with FLOT Improves Survival Among Patients with Resectable Oesophageal... Her Massive Weight Loss Helped Her Feel A Lump In Her... Female Representation at the Top of the Oncology Field Has Hit...
